On 24 September, uniQure announced exciting topline results for their Phase 1/2 study of AMT-130 in HD. The high dose of AMT-130 met the study’s primary endpoint by demonstrating statistically significant slowing of disease progression (as assessed by the composite Unified Huntington’s Disease Rating Scale) at 36 months compared to a propensity score-matched external control […]
Kategori: Uncategorized
Enroll-HD periodic dataset – PDS7
The seventh release of the Enroll-HD periodic dataset, PDS7, has been fully curated and is now available. PDS7 contains data from 30,511 Enroll-HD study participants encompassing 112,992 study visits, making it one of the largest cohort datasets available to researchers. Read more here. […]
EHDN LESLEY JONES SEED FUND PROGRAM
The program is currently open and receiving applications! Head here for more information and the application form Deadline: 1st November 2025 23:59 CET […]
next steps for Pridopidine
On 25 July, Prilenia shared that the application for pridopidine had been rejected for marketing authorisation in HD by the European Medicines Agency’s Committee for Medicinal Products for Human Use. The application was based on post-hoc analyses from the EHDN-endorsed, Phase 3 PROOF-HD study, suggesting that the orally administered sigma-1 receptor agonist may offer potential […]
EHDN Imaging Working Group (iWG) newsletter – edition 3
The EHDN Imaging Working Group has now produced its third newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Imaging Working Group (iWG) NEWSLETTER Edition 3 | July 2025 […]
EHDN Newsletter – 55th edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
EHDN Imaging Working Group (iWG) newsletter – edition 2
The EHDN Imaging Working Group is now producing a regular newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Welcome to the inaugural edition of the Imaging Working Group (iWG) NEWSLETTER Edition 2 | March 2025 […]
Postcard from Palm Springs 2025
Published by CHDI, ‘Postcards From…’ is a series of short videos aimed at non-scientists that conveys the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease Therapeutics Conference held (most usually) in Palm Springs, California. Beginning in 2006, this series of conferences is a unique forum where researchers from academia meet […]
MDS-PAS and EHDN Joint Online Course Series: Multidisciplinary Management of Huntington’s Disease
Serie de Cursos Conjuntos en Línea MDS-PAS y EHDN: Manejo Multi- disciplinario de la Enfermedad de Huntington Course Format Start Date End Date Live Online Fri, Aug 15, 2025 Fri, Aug 22, 2025 Program Description Serie de Cursos Conjuntos en Línea MDS-PAS y EHDN: Manejo Multi- disciplinario de la Enfermedad de Huntington: Retos actuales y […]
11th Congress of the European Academy of Neurology
Helsinki 2025 – June 21-24 […]